Dosing and administration SOLIRIS® (eculizumab) is indicated for the treatment of refractory generalised myasthenia gravis (gMG) in patients aged 6 years and above who are anti-acetylcholine receptor (AChR) antibody-positive.1 Please consult the Summary of Product Characteristics prior to prescribing.
advance I am a healthcare professional registered in the EU I am not a
healthcare professional
Dosing schedule for adult patients with refractory gMG (≥ 18 years of age):1

Dosing for adult patients with anti-AChR+ refractory gMG consists of a 4-week initial induction phase followed by dosing every 14 ± 2 days1

  • Initial induction phase: 900 mg of SOLIRIS® administered via a 25- to 45- minute (35 minutes ± 10 minutes) intravenous infusion every week for the first 4 weeks1
  • Maintenance phase: 1200 mg of SOLIRIS® administered via a 25- to 45 minute (35 minutes ± 10 minutes) intravenous infusion for the fifth week, followed by 1200 mg of SOLIRIS® administered via a 25- to 45 minute (35 minutes ± 10 minutes) intravenous infusion every 14 ± 2 days1

Supplemental dosing of SOLIRIS® is required in patients receiving plasmapheresis, or plasma exchange, or frozen plasma infusion1

For further details or dosing in paediatric patients with gMG please refer to the product SmPC available here
Learn more
AChR, acetylcholine receptor; gMG, generalised myasthenia gravis.
Healthcare professionals are asked to report any suspected adverse reactions. Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com/
SOLIRIS® (eculizumab) EU Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf. Last accessed: February 2024.